Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan and Bevacizumab in Recurrent Platinum-Sensitive Ovarian Cancer
NCT07504588Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in ovarian cancer, sponsored by National Cancer Institute. Started Sep 2026; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07504588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504588.